About Breonics: Overview Continued

Innovative Biomedical Products

BREONICS, Inc. is an emerging biomedical research and discovery company that is developing innovative products for the clinical organ transplantation, tissue replacement and gene therapeutic markets. Incorporated in 1996, the company has built upon strong collaborative and strategic relationships. Working closely with world renowned clinical transplantation organizations, research centers and major pharmaceutical companies provides the resources to overcome development obstacles and rapidly advance the company's technologies to market.

Cheap research paper writing essays247 on request

BREONICS was first to focus its efforts on developing technology that overcomes the barriers to expanding the organ donor pool, thereby offering a solution to the chronic shortage of organs. Based upon over fifteen years of research by its founding personnel, the company has 12 issued patents and another 15 pending that cover its proprietary equipment, methods and processes for resuscitating, evaluating, repairing and pre-treating organs intended for clinical transplantation.

Funding

The company is a privately held corporation funded by venture capital, grants and contracts from the National Institutes of Health, (NIH) and National Technology Test Bed (NMTB) and research and development support from strategic partnering. Research revenues for fiscal years 2008 and 2009 were approximately $1.75 million. Revenues for 2002 are projected to reach $3.3 million. Initial investors include Techno Ventures Management GmbH, Munich (TVM), Alpinvest and Krediet Bank Luxembourg (KBL).

Facilities

Breonics facilities include its research and manufacturing park located in Orange County, New York that provides FDA compliant GMP (Good Manufacturing Procedure) and GLP (Good Laboratory Procedure) facilities for advanced product development and manufacture. Cell culture and perfusion laboratories are located in Schenectady, New York, preclinical research is conducted at East Carolina University Medical Center, Greenville, North Carolina.

Currently Under Development

The company's research and development program includes:

1. Exsanguinous Metabolic Support (EMS), a technology that consists of the proprietary solutions, equipment and process to resuscitate, evaluate, maintain and repair warm, ischemically damaged organs and tissue.
2. Organ Specific Immunosuppression that includes ENDOMATIRX, which may be the first successful therapy to pre-treat organs prior to transplantation in order to induce tolerance in the recipient and eliminate the need for systemic immunosuppression.